Equities Analysts Offer Predictions for ACAD FY2027 Earnings

Key Points

• HC Wainwright raised ACADIA Pharmaceuticals' FY2027 earnings per share estimate from $2.43 to $2.49, maintaining a "Buy" rating with a price target of $32.00.
• ACADIA Pharmaceuticals reported a quarterly earnings of $0.16 per share, exceeding expectations and showcasing a 9.4% year-over-year revenue growth.
• Institutional investors and hedge funds own 96.71% of ACADIA's stock, indicating strong confidence in the company's prospects.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Analysts at HC Wainwright lifted their FY2027 earnings per share estimates for shares of ACADIA Pharmaceuticals in a note issued to investors on Thursday, August 7th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will post earnings of $2.49 per share for the year, up from their previous estimate of $2.43. HC Wainwright has a "Buy" rating and a $32.00 price objective on the stock. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals' FY2028 earnings at $2.70 EPS and FY2029 earnings at $2.85 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.16 EPS for the quarter, topping analysts' consensus estimates of $0.14 by $0.02. The business had revenue of $264.57 million during the quarter, compared to the consensus estimate of $263.07 million. ACADIA Pharmaceuticals had a return on equity of 15.38% and a net margin of 21.80%. The business's revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.20 EPS.

A number of other research firms also recently commented on ACAD. Oppenheimer restated a "market perform" rating and set a $22.00 price objective (up from $19.00) on shares of ACADIA Pharmaceuticals in a report on Thursday, June 26th. The Goldman Sachs Group upped their price objective on ACADIA Pharmaceuticals from $15.00 to $17.00 and gave the stock a "sell" rating in a report on Thursday. Needham & Company LLC reaffirmed a "buy" rating and set a $30.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, June 26th. JMP Securities upped their price objective on shares of ACADIA Pharmaceuticals from $37.00 to $38.00 and gave the company a "market outperform" rating in a research report on Thursday. Finally, Bank of America upped their price objective on shares of ACADIA Pharmaceuticals from $18.00 to $23.00 and gave the company a "hold" rating in a research report on Thursday, June 5th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $28.53.

ACADIA Pharmaceuticals Stock Up 1.3%

Shares of ACAD stock traded up $0.33 on Friday, reaching $24.73. 573,862 shares of the stock were exchanged, compared to its average volume of 2,172,956. The stock has a market cap of $4.14 billion, a P/E ratio of 18.65, a price-to-earnings-growth ratio of 6.64 and a beta of 0.70. The firm has a 50 day moving average of $22.32 and a two-hundred day moving average of $19.21. ACADIA Pharmaceuticals has a 1-year low of $13.40 and a 1-year high of $25.23.

Insider Activity at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, Director Laura Brege sold 14,446 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $21.78, for a total value of $314,633.88. Following the transaction, the director owned 15,095 shares in the company, valued at approximately $328,769.10. The trade was a 48.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider James Kihara sold 4,000 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $22.50, for a total transaction of $90,000.00. Following the completion of the transaction, the insider owned 20,395 shares in the company, valued at approximately $458,887.50. This trade represents a 16.40% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 20,446 shares of company stock worth $454,634 over the last quarter. 26.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACAD. Allspring Global Investments Holdings LLC boosted its stake in shares of ACADIA Pharmaceuticals by 645.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 310,332 shares of the biopharmaceutical company's stock valued at $5,065,000 after buying an additional 268,714 shares during the period. GAMMA Investing LLC raised its holdings in ACADIA Pharmaceuticals by 627.3% in the 1st quarter. GAMMA Investing LLC now owns 3,513 shares of the biopharmaceutical company's stock worth $58,000 after acquiring an additional 3,030 shares during the period. Concurrent Investment Advisors LLC bought a new position in ACADIA Pharmaceuticals in the 1st quarter worth $247,000. Amalgamated Bank increased its holdings in shares of ACADIA Pharmaceuticals by 757.7% during the 1st quarter. Amalgamated Bank now owns 35,002 shares of the biopharmaceutical company's stock worth $581,000 after purchasing an additional 30,921 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of ACADIA Pharmaceuticals by 28.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,086,840 shares of the biopharmaceutical company's stock valued at $19,932,000 after acquiring an additional 243,082 shares in the last quarter. Institutional investors and hedge funds own 96.71% of the company's stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.